Prime Medicine (PRME) Free Cash Flow (2021 - 2026)

Prime Medicine has reported Free Cash Flow for 6 years, with the latest figure at -$42.9 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 16.29% year-over-year to -$42.9 million; the trailing twelve-month figure through Mar 2026 stood at -$154.3 million (down 46.6% YoY), and the FY2025 full-year result was -$162.7 million, down 31.17% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$42.9 million, down from -$33.1 million in the prior quarter.
• The five-year high for Free Cash Flow was $15.2 million in Q4 2024, with the low at -$70.0 million in Q1 2024.
• Historically, Free Cash Flow has averaged -$37.4 million across 5 years, with a median of -$39.1 million in 2025.
• Annual changes were most pronounced in 2024 — Free Cash Flow soared 133.26% — and 2025, when it sank 317.93%.
• Prime Medicine's Free Cash Flow stood at -$30.8 million in 2022, then plunged by 48.33% to -$45.7 million in 2023, then surged by 133.26% to $15.2 million in 2024, then sank by 317.93% to -$33.1 million in 2025, then dropped by 29.57% to -$42.9 million in 2026.
• The last three Free Cash Flow figures came in at -$42.9 million (Q1 2026), -$33.1 million (Q4 2025), and -$39.1 million (Q3 2025), per Business Quant data.